retatrutide trial results phase 2 Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people Interesting data from the @EliLillyandCo

This reflects central appetite circuit modulation in the brain

Conservative titration protocol This approach prioritizes comfort and minimal side effects above all else

Understanding the escalation protocol is essential when learning how to get retatrutide

If uncertainty exists about appropriate placement, patients should consult their prescribing physician or a diabetes care and education specialist before proceeding with injections in unfamiliar areas

Total loss by week 24 typically ranges from 18-22% based on Phase 2 data

Your clinician will likely evaluate: Your Primary Goal: Is the focus blood sugar control, weight loss, or both